Table 2. Clinicopathological data and results of univariate and multivariate analysis of prognostic factors for overall survival in patients with resected adenocarcinoma of the pancreato-biliary system (n = 86).

In multivariate analysis, overall survival was adjusted by pathological tumor stage (pT) and lymph node status (pN).

	Number of patients	Median overall survival (months)	Univariate		Multivariate
			Crude HR (95% CI)	p value	Adjusted HR (95% CI)	p value
Age (years)
> 66a	42	32	1
≤ 66	44	30	1.14 (0.69–1.88)	0.601
Gender
Fa	47	30	1
M	39	33	0.77 (0.47–1.29)	0.322
Pathological tumor stage				<0.001 ***
pTis	1
pT1	10	78	0.46 (0.19–1.10)	0.081 .
pT2	27	34	0.75 (0.42–1.34)	0.330
pT3a	39	25	1
pT4	9	7	3.37 (1.51–7.52)	0.003 **
Lymph node status				<0.001 ***
pNX	10
pN0	28	49	0.36 (0.20–0.65)	<0.001 ***
pN1 / 2 (n = 2)	48	19	1
Immunohistochemical type				<0.001 ***		0.001 **
Extrahepaticpancreatobiliarya	57	24	1		1
Intestinal	8	54	0.31 (0.11–0.87)	0.026 *	0.19 (0.05–0.72)	0.014 *
Intrahepaticcholangiocarcinoma	14	109	0.26 (0.11–0.61)	0.002 **	0.61 (0.22–1.69)	0.340
Anatomicalclassification				0.068 .		0.005 **
Ductal pancreatic adenocarcinomaa	30	19	1		1
Ampullarycarcinoma	12	31	0.66 (0.31–1.42)	0.290	0.90 (0.40–2.04)	0.799
Distal bile duct cancer	6	60	0.52 (0.18–1.49)	0.223	0.68 (0.20–2.31)	0.536
Gallbladder cancer	11	26	0.91 (0.42–1.95)	0.803	1.40 (0.59–3.32)	0.447
Perihilar cholangiocarcinoma	9	NAb	0.25 (0.08–0.71)	0.010 *	0.58 (0.19–1.83)	0.356
Intrahepatic cholangiocarcinoma	18	56	0.49 (0.24–1.00)	0.051 .	1.78 (0.74–4.26)	0.195

HR, hazard ratio; CI, confidence interval; NA, not available (median survival time not reached)

^a Baseline category

^b Median overall survival not reached at end of follow-up; restricted mean = 77 months

Significance codes

*** P ≤ 0.001

** P ≤ 0.01

* P ≤ 0.05, and P ≤ 0.1